<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034783</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-NM-EX4</org_study_id>
    <nct_id>NCT05034783</nct_id>
  </id_info>
  <brief_title>[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients</brief_title>
  <official_title>A Pilot Prospective Comparison of [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucagon-like peptide-1 receptor (GLP-1R)-targeted PET imaging with 68Ga-labeled compounds is&#xD;
      able to provide superior sensitivity and specificity to detect insulinoma, like the widely&#xD;
      studied [68Ga]Ga-NOTA-exendin-4. This pilot study was prospectively designed to evaluate the&#xD;
      early dynamic distribution of [68Ga]Ga-HBED-CC-exendin-4, a novel radiopharmaceutical&#xD;
      targeting GLP-1R, which was compared with [68Ga]Ga-NOTA-exendin-4 in the same group of&#xD;
      insulinoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulinoma is the most common cause of endogenous hyperinsulinemic hypoglycemia in adult&#xD;
      patients without diabetes. The only curative treatment of an insulinoma is its surgical&#xD;
      removal. Therefore, exact preoperative localization of the insulinoma is critical to planning&#xD;
      the surgical intervention. MR imaging, CT, or endoscopic ultrasound is normally used to&#xD;
      localize insulinomas. However, the small size of the tumors (often,1 cm) limits the&#xD;
      sensitivity of these methods. In recent years, a new receptor-targeted imaging technique,&#xD;
      glucagon-like peptide-1 receptor (GLP-1R) imaging, for detecting insulinoma has been&#xD;
      established. GLP-1R is expressed on benign insulinoma cell surfaces with very high incidence&#xD;
      (&gt;90%) and density (8,133 dpm/mg of tissue). No other peptide receptor has been found to&#xD;
      exhibit such high expression levels in insulinoma. [68Ga]Ga-HBED-CC-exendin-4, a novel&#xD;
      radiopharmaceutical targeting GLP-1R, with the urea fragment of a conjugate that employs the&#xD;
      HBED-CC chelator for labeling with 68Ga in order to In order to reduce the accumulation of&#xD;
      radioactivity in the kidneys. This pilot study was prospectively designed to evaluate the&#xD;
      early dynamic distribution of [68Ga]Ga-HBED-CC-exendin-4 compared with&#xD;
      [68Ga]Ga-NOTA-exendin-4 in the same group of Insulinoma patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic parameters</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the early dynamic distribution (SUVmax in tumor lesions and SUVmean in normal organs at different time points) of [68Ga]Ga-HBED-CC-exendin-4 in comparison with [68Ga]Ga-NOTA-exendin-4 in the same group of insulinoma patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic value</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Sensitivity and Specificity of [68Ga]Ga-HBED-CC-exendin-4 for insulinoma in comparison with [68Ga]Ga-NOTA-exendin-4 PET/CT.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>GLP-1R expression and SUV</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Correlation between GLP-1R expression and SUV in PET</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Insulinoma</condition>
  <arm_group>
    <arm_group_label>[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/ CT scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of Insulinoma PET/CT imaging: In two consecutive days each patient underwent a 60-min dynamic PET/CT scan after intravenous administration of [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[68Ga]Ga-HBED-CC-exendin-4</intervention_name>
    <description>Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) [68Ga]Ga-HBED-CC-exendin-4. Tracer doses of [68Ga]Ga-HBED-CC-exendin-4 will be used to image lesions of insulinoma by PET/CT.</description>
    <arm_group_label>[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/ CT scan</arm_group_label>
    <other_name>[68Ga]Ga-HBED-CC-exendin-4 injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[68Ga]Ga-NOTA-exendin-4</intervention_name>
    <description>Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) [68Ga]Ga-NOTA-exendin-4. Tracer doses of [68Ga]Ga-NOTA-exendin-4 will be used to image lesions of insulinoma by PET/CT.</description>
    <arm_group_label>[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/ CT scan</arm_group_label>
    <other_name>[68Ga]Ga-NOTA-exendin-4 injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed treated or untreated insulinoma patients;&#xD;
&#xD;
          -  [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT within two consecutive&#xD;
             days;&#xD;
&#xD;
          -  signed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy;&#xD;
&#xD;
          -  breastfeeding;&#xD;
&#xD;
          -  known allergy against exendin-4;&#xD;
&#xD;
          -  any medical condition that in the opinion of the investigator may significantly&#xD;
             interfere with study compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaohui Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhaohui Zhu, MD</last_name>
    <phone>86-13611093752</phone>
    <email>13611093752@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guochang Wang, MD</last_name>
    <phone>86-18516822732</phone>
    <email>guochang1007@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaohui Zhu, MD</last_name>
      <phone>86-13611093752</phone>
      <email>13611093752@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

